Primary XXXX other than @entity1892 : a descriptive analysis of clinical features and treatment outcomes.

@entity1 @entity706 @entity75 @entity3191 @entity784 @entity2109 @entity149 @entity1892 @entity1500 @entity3554
@entity1892 ( @entity1892 ) constitutes most primary central nervous system (CNS) @entity706 (PCNSL), whereas T-cell, low-grade and @entity2109 ( @entity2109 ) are rarely encountered. Due to the paucity of cases, little is known about the clinical features and treatment outcomes of PCNSL other than @entity1892 . The objective of this study was to describe the clinical characteristics and outcomes for @entity1 with PCNSL other than @entity1892 . Fifteen @entity1 , newly diagnosed with PCNSLs other than @entity1892 between 2000 and 2010, were included. The male to female ratio was 0.67:1 with a median age of diagnosis of 31 years (range 18-59). Pathologic distributions were as follows: @entity3191 ( @entity3191 ; n=7), @entity1892 ( @entity1892 ; n=1), @entity706 ( @entity706 ; n=2), @entity2109 (n=1), other unspecified (T-cell lineage, n=2; B-cell lineage, n=2). Thirteen @entity1 (87%) showed Eastern Cooperative Oncology Group performance score (ECOG PS) 1-2. The remaining two were one @entity3191 @entity1 and one @entity2109 @entity1 . Of the nine @entity1 with @entity784 , five (56%) had @entity75 , and one (20%) with @entity706 of the five @entity1 with @entity1892 showed a single lesion. @entity3554 was identified in two @entity1 (one with @entity2109 and one with unspecified @entity1892 ). Two @entity1 (22%) with @entity784 died 7.7 and 23.3 months later, respectively, due to disease progression, despite HD- @entity1500 -based therapy. Six @entity1 with @entity784 (6/9, 66.7%) and four @entity1 with low-grade @entity1892 (4/5, 80%) achieved complete response and have survived without relapse (Table 3). One @entity1 with @entity2109 showed poor clinical features with ECOG PS 3, deep structure, multifocal, and @entity3554 , and died 7.6 months after the initiation of treatment. In comparison with previously reported DLBCLs (median OS 6.4 years, 95% CI 3.7-9.1 years), @entity784 showed equivocal or favorable clinical outcomes and low-grade @entity1892 , such as @entity1892 and @entity706 , had a good prognosis. However, primary CNS @entity2109 presented poor clinical outcomes and showed a comparatively aggressive clinical course. In conclusion, primary @entity149 other than @entity1892 occurred more in younger @entity1 and showed a generally good prognosis, except for @entity2109 . Further research on treatment strategies for @entity2109 is needed.
